This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Nu Skin (NUS) More Than Double in a Year: Will Momentum Stay?
by Zacks Equity Research
Nu Skin (NUS) is benefiting from initiatives to strengthen sales leader and expand customer base. Also, the company's focus on digital operations is impressive.
The Estee Lauder (EL) to Raise Stake in DECIEM to Aid Growth
by Zacks Equity Research
The Estee Lauder (EL) will increase its stake in DECIEM from nearly 29% to roughly 76% for almost $1 billion. The deal is likely to be concluded during the quarter ending Jun 30.
4 Factors That Make The Estee Lauder (EL) a Promising Pick
by Zacks Equity Research
The Estee Lauder's (EL) impressive online business is driving growth. Also, the company's Skin Care portfolio is performing well.
Newell Brands (NWL) Beats Q4 Earnings & Sales Estimates
by Zacks Equity Research
Despite COVID-related woes, robust consumption patterns and higher demand for certain categories aided Newell Brands' (NWL) Q4 results.
Nu Skin (NUS) Tops Q4 Earnings Estimates, Raises Dividend
by Zacks Equity Research
Growth in sales leaders and customer base drove Nu Skin's (NUS) fourth-quarter 2020 results. Notably, earnings and revenues increased year over year.
Coty (COTY) Stock Slips 15% Despite Q2 Earnings & Sales Beat
by Vrishali Bagree
Coty's (COTY) second-quarter fiscal 2021 results reflect lower earnings and sales due to the pandemic-related woes, especially in travel retail. However, e-commerce strength and cost-saving efforts aid.
NUS or HELE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NUS vs. HELE: Which Stock Is the Better Value Option?
Estee Lauder (EL) Q2 Earnings Beat Estimates, Sales Up Y/Y
by Zacks Equity Research
Estee Lauder's (EL) second-quarter fiscal 2021 sales and earnings increase year over year. However, results reflect impact of some retail store closures and lower traffic in reopened stores amid COVID-19.
Clorox (CLX) Q2 Earnings, Sales Top Estimates on Strong Demand
by Zacks Equity Research
Clorox's (CLX) Q2 sales benefit from double-digit sales growth in the majority of the segments, fueled by strong product demand due to the coronavirus outbreak and related shift in trends.
Zacks Industry Outlook Highlights: Estee Lauder, Helen of Troy, Coty, Nu Skin Enterprises and e.l.f. Beauty
by Zacks Equity Research
Zacks Industry Outlook Highlights: Estee Lauder, Helen of Troy, Coty, Nu Skin Enterprises and e.l.f. Beauty
Inter Parfums (IPAR) Ups 2020 Earnings View on Solid Q4 Sales
by Zacks Equity Research
Inter Parfums' (IPAR) sales increase year over year in fourth-quarter 2020. Management raises 2020 earnings guidance.
5 Cosmetics Stocks Looking Good Amid Industry Challenges
by Vrishali Bagree
The Zacks Cosmetics industry is battling coronavirus woes like weak travel retail, reduced traffic and low makeup demand. However, high demand for personal care products bodes well for EL, HELE, COTY, NUS and ELF, which are focused on adapting to the changing market trends.
NUS or EL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NUS vs. EL: Which Stock Is the Better Value Option?
Are Investors Undervaluing Nu Skin Enterprises (NUS) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Procter & Gamble (PG) Q2 Earnings & Sales Beat, FY21 View Up
by Zacks Equity Research
Procter & Gamble's (PG) Q2 results gain from solid performance across all segments as well as a rise in organic shipment volumes, improved pricing and mix. Encouragingly, it lifts fiscal 2021 view.
3 Factors That Makes Helen of Troy (HELE) a Promising Pick
by Zacks Equity Research
Helen of Troy (HELE) is focused on making solid investments in its Leadership Brands. Also, strength in the company's online business is yielding.
Inter Parfums' (IPAR) Subsidiary to Buy Office Building Complex
by Zacks Equity Research
Inter Parfums' (IPAR) subsidiary Interparfums SA to buy property in Paris, which will be used as its headquarters. Management expects to close the transaction during spring of 2021.
Why Nu Skin (NUS) Could Beat Earnings Estimates Again
by Zacks Equity Research
Nu Skin (NUS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Has Nu Skin Enterprises (NUS) Outpaced Other Consumer Staples Stocks This Year?
by Zacks Equity Research
Is (NUS) Outperforming Other Consumer Staples Stocks This Year?
Nu Skin (NUS) Looks Buoyant, Stock Up More Than 35% in a Year
by Zacks Equity Research
Nu Skin (NUS) has been benefiting from focus on innovation as well as commitment to strengthening sales leaders.
Estee Lauder (EL) Looks Solid on Online Business & Savings
by Zacks Equity Research
Estee Lauder (EL) is implementing new technology and digital experiences to boost online sales. Also, strength in the Skin Care category is driving growth.
Helen of Troy's (HELE) Q3 Earnings Beat Estimates, Sales Up Y/Y
by Zacks Equity Research
Helen of Troy's (HELE) third-quarter fiscal 2021 results reflect strength across the Beauty and the Health & Home segments along with gains in online business.
Is Nu Skin Enterprises (NUS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
NUS vs. EL: Which Stock Is the Better Value Option?
by Zacks Equity Research
NUS vs. EL: Which Stock Is the Better Value Option?
Coty (COTY) Aids Beauty Categories With Kim Kardashian West Deal
by Zacks Equity Research
Coty (COTY) buys a 20% stake in Kim Kardashian West's business. The company's industry knowledge and Kim Kardashian West's robust following are likely to benefit both.